Berlin. The CytoSorb therapy is safe, easy to handle and able to stabilize the overshooting immune system. These are some of the main results of the second international CytoSorb users meeting, which took place in the first days of October 2015. We thank all 110 participants from 18 countries having joined this platform that enabled users, partners and distributors to exchange their experiences with CytoSorb. Case reports, case series and interim results from several controlled pilot studies were presented and discussed. This was a clear step in CytoSorbents’ continuous strategy to reach a high level of clinical evidence.
Key findings of the symposium include …
Key findings of the symposium include:
Safety & Ease of use
Several CytoSorb users showed that the therapy is being used in real-world situations much earlier as an adjunctive therapy to control deadly inflammation and to treat life-threatening illnesses, rather than as a last resort therapy.
Broad indication range
Experience with the application of Cytosorb in patients with myoglobinemia.
A comprehensive overview on the mechanisms of the body’s host response, current concepts of the SIRS-MARS-CARS continuum and potential therapeutic avenues to interfere with the disturbed systemic inflammatory response
A detailed summary on the epidemiology and pathophysiology of sepsis, the rationale for cytokine elimination, conventional techniques and non-specific adsorption approaches with focus on the CytoSorb technology
Experimental protocol details and first preliminary results on the planned in-vitro study investigating the impact of CytoSorb on drug levels
Most recent evidence on the association between different patterns of cytokines and outcome, CytoSorb’s underlying operating principle and future perspectives for the technology.
Overview on the objectives, methods and status of the currently implemented international CytoSorb registry.
Experience using CytoSorb in patients with severe sepsis, septic shock, acute liver failure and rhabdomyolysis
Interim analysis results of the first 10 patients included into the ACESS trial.
CytoSorb Therapy in a case of sepsis-associated liver dysfunction.
Case series where CytoSorb was successfully used in 10 patients with septic shock
Interim analysis results on 16 patients treated with CytoSorb for post cardiopulmonary bypass SIRS.
Preliminary interim results of a prospective pilot study using CytoSorb in patients undergoing elective coronary artery bypass grafting (CABG)